Unlock instant, AI-driven research and patent intelligence for your innovation.

Composition of polyphyllin VII and multiple myeloma clinical drugs and application

A technology for multiple myeloma and salicylate saponins, applied in the field of medicine, can solve problems such as unresearched

Active Publication Date: 2021-03-02
CENT SOUTH UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Preclinical studies have shown that PP7 has broad-spectrum antitumor activity, including lung cancer, nasopharyngeal cancer, liver cancer, breast cancer, oral cancer, colon cancer, etc., but it has not been studied in MM so far

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition of polyphyllin VII and multiple myeloma clinical drugs and application
  • Composition of polyphyllin VII and multiple myeloma clinical drugs and application
  • Composition of polyphyllin VII and multiple myeloma clinical drugs and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] CCK-8 method was used to detect the synergistic effect on MM cells after combined use of barley saponin Ⅶ and bortezomib in different concentration ratios on MM cells ANBL6 cells.

[0031] Experimental steps:

[0032] (1) ANBL6 cells (professor Zhou Wen from the Cancer Institute of Central South University) grew to the logarithmic phase, resuspended the cells into a 15mL centrifuge tube, and blown and mixed well. Cells were diluted 10 times in a 1.5 ml centrifuge tube, and the cell density was calculated by using a cytometer.

[0033] (2) Set the well plate group without adding cells and only complete medium (RPMI-1640 medium + 10% BI fetal bovine serum + 1% double antibody) and the control group without adding drugs, only cells and complete medium, each The concentration was set in 4 replicate wells.

[0034] (3) Adding different concentration ratios of diploside VII and bortezomib (0μM+0nM, 0μM+5nM, 0μM+7.5nM, 0μM+10nM, 0.5μM+0nM, 0.5μM+5nM, 0.5μM+ Inoculated cells...

Embodiment 2

[0046] CCK-8 method was used to detect the synergistic effect on MM cells after combined use of different concentrations of barley saponin Ⅶ and bortezomib on MM cells ANBL6-BR cells.

[0047] Experimental steps:

[0048] (1) ANBL6-BR (professor Zhou Wen from the Cancer Institute of Central South University) cells grow to the logarithmic phase, resuspend the cells in a 15mL centrifuge tube, and blow and mix well. Cells were diluted 10 times in a 1.5 ml centrifuge tube, and the cell density was calculated by using a cytometer.

[0049] (2) Set the well plate group without adding cells and only complete medium (RPMI-1640 medium + 10% BI fetal bovine serum + 1% double antibody) and the control group without adding drugs, only cells and complete medium, each The concentration was set in 4 replicate wells.

[0050] (3) Adding different concentration ratios of diploside VII and bortezomib (0μM+0nM, 0μM+40nM, 0μM+80nM, 0μM+160nM, 0.5μM+0nM, 0.5μM+40nM, 0.5μM+80nM , 0.5μM+160nM, 1μ...

Embodiment 3

[0063] Using CCK-8 method to detect the effect of saponin Ⅶ and bortezomib on MM cells alone and in combination on primary CD138 in MM patients + Effect on cell viability.

[0064] Experimental steps:

[0065] (1) Bone marrow mononuclear cells from MM patients (from Hunan Cancer Hospital) were isolated with lymphocyte separation medium (purchased from Tianjin Haoyang Biological Products Technology Co., Ltd.).

[0066] (2) Sorting CD138 in mononuclear cells with CD138 magnetic beads + cell.

[0067] (3) CD138 + The primary cells were resuspended in a 15mL centrifuge tube and mixed by blowing. Cells were diluted 10 times in a 1.5 ml centrifuge tube, and the cell density was calculated by using a cytometer.

[0068] (4) Set the well plate group without adding cells and only complete medium (RPMI-1640 medium + 10% BI fetal bovine serum + 1% double antibody) and the control group without adding drugs, only cells and complete medium, each The concentration was set in 4 replica...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a composition of paris polyphylla saponin VII and multiple myeloma clinical medicine and an application. The composition of the traditional Chinese medicine monomer paris polyphylla saponin VII and the multiple myeloma clinical medicine bortezomib or adriamycin is used for preparing the medicine for treating the multiple myeloma. Compared with single use of polyphyllin VIIor multiple myeloma clinical drugs, the pharmaceutical composition provided by the invention adopts combination of polyphyllin VII and bortezomib or combination of polyphyllin VII and adriamycin, andhas a better effect of inhibiting cell proliferation. The composition greatly improves the sensitivity of multiple myeloma cells to bortezomib or adriamycin, and is especially suitable for treating recurrent / refractory multiple myeloma patients.

Description

technical field [0001] The invention relates to a medicine for treating multiple myeloma, in particular to the composition and application of papaya saponin VII and clinical medicine for multiple myeloma. It belongs to the field of medical technology. Background technique [0002] Multiple myeloma (multiple myeloma, MM), the second most common hematological malignancy (13%), is a genetically complex clonal plasma cell malignancy, accounting for 1% of all newly diagnosed tumors. MM is prone to occur in middle-aged and elderly people. With the aging of the population at home and abroad, the incidence of MM is increasing year by year. Although new targeted therapies such as proteasome inhibitor bortezomib and some immunomodulators have emerged in recent years, the treatment remission rate of MM patients has increased significantly. However, cell drug resistance and disease recurrence caused by treatment resistance will make MM enter the refractory stage, which poses new chall...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7048A61K38/05A61K31/704A61P35/00A61P7/00
CPCA61K31/7048A61K38/05A61K31/704A61P35/00A61P7/00A61K2300/00
Inventor 萧小鹃王海勤刘静梁龙胡磊
Owner CENT SOUTH UNIV